{"gene":"BRMS1","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":2000,"finding":"BRMS1 was identified as a novel metastasis suppressor gene encoded on chromosome 11q13.1-q13.2; stable transfection of BRMS1 cDNA into MDA-MB-435 and MDA-MB-231 breast carcinoma cells significantly suppressed metastasis to lungs and regional lymph nodes without inhibiting tumorigenicity.","method":"Differential display, stable transfection, orthotopic xenograft mouse model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean loss/gain-of-function in two cell lines with defined in vivo metastatic phenotype, independently replicated across multiple subsequent studies","pmids":["10850410"],"is_preprint":false},{"year":2000,"finding":"BRMS1 re-expression restored homotypic gap junctional intercellular communication (GJIC) in human breast carcinoma cells, and modestly inhibited motility (~30–60%) and soft-agar growth in MDA-MB-435; no consistent effects on adhesion to ECM components, MMP/heparanase expression, invasion, or upregulation of other metastasis suppressors (NM23, KAI1, KiSS1, E-cadherin) were detected.","method":"Gap junction assay, motility assay, soft-agar colony formation, adhesion assays, RT-PCR","journal":"Clinical & experimental metastasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro assays in single lab; gap junction restoration replicated in subsequent work","pmids":["11827072"],"is_preprint":false},{"year":2003,"finding":"BRMS1 interacts with retinoblastoma-binding protein 1 (RBP1/RBBP1) and at least seven members of the mSin3 histone deacetylase (HDAC) complex; it co-immunoprecipitates enzymatically active HDAC proteins and represses transcription when tethered to a Gal4 promoter in vivo. BRMS1 exists in large mSin3 complexes (~1.4–1.9 MDa) and in smaller HDAC1-containing complexes. The C-terminal 42 amino acids are not critical for interaction with most of the mSin3 complex.","method":"Yeast two-hybrid, co-immunoprecipitation, HDAC enzymatic assay, Gal4-reporter transcription repression assay, deletion analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (Y2H, co-IP, enzymatic activity, reporter assay), replicated by multiple subsequent studies","pmids":["14581478"],"is_preprint":false},{"year":2002,"finding":"BRMS1 suppresses metastasis (but not tumorigenicity) in human melanoma cell lines MelJuSo and C8161.9 in vivo, and restores homotypic gap junctional intercellular communication and reduces invasion in collagen sandwich assays in these cells.","method":"Stable transfection, orthotopic xenograft, collagen sandwich invasion assay, GJIC assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean gain-of-function with defined in vivo phenotype in two melanoma cell lines, single lab","pmids":["11822878"],"is_preprint":false},{"year":2004,"finding":"BRMS1 was identified as a component of the mSin3A/HDAC1 complex alongside RBP1 and p33(ING1b); a BRMS1-homologue, p40 (also homologous to yeast Sds3 and mammalian mSds3), was biochemically purified from this complex and the associated complex showed strong HDAC activity.","method":"Biochemical purification, mass spectrometry, HDAC activity assay, Gal4 transcription repression reporter","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — biochemical purification with enzymatic activity confirmation in single lab","pmids":["15451426"],"is_preprint":false},{"year":2006,"finding":"BRMS1 is stabilized by the Hsp90 chaperone and its turnover is proteasome-dependent; BRMS1 interacts with chaperones DNAJB6 (MRJ), Hsp90, and Hsp70, as well as with class II HDACs 4, 5, and 6, in addition to core mSin3 complex components.","method":"Yeast two-hybrid, immuno-affinity chromatography, co-immunoprecipitation, proteasome inhibitor experiments","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and biochemical validation, single lab, multiple orthogonal approaches","pmids":["16919237"],"is_preprint":false},{"year":2007,"finding":"BRMS1 inhibits osteopontin (OPN) transcription by abrogating NF-κB activation at a specific NF-κB binding site in the OPN promoter; HDAC3 participates in suppression of OPN via this NF-κB site.","method":"Luciferase reporter assays with OPN promoter deletions, EMSA, chromatin immunoprecipitation (ChIP)","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and EMSA confirm NF-κB binding site, luciferase reporters validate functional suppression; single lab","pmids":["17227585"],"is_preprint":false},{"year":2008,"finding":"BRMS1 inhibits multiple steps of the metastatic cascade: fewer BRMS1-expressing cells reach the lungs or bone after intravascular injection (suggesting increased cell death in transit), and most cells reaching secondary sites fail to proliferate (inhibition of colonization); BRMS1 expression also increases susceptibility to anoikis in vitro.","method":"Cardiac ventricle injection xenograft model, quantitative in vivo imaging, poly-HEMA anoikis assay","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo model with direct quantification of metastatic steps plus corroborating in vitro anoikis assay; single lab","pmids":["18276787"],"is_preprint":false},{"year":2009,"finding":"BRMS1 contains one functional nuclear localization signal (NLS) that is necessary and sufficient for nuclear import, mediated specifically by importin α6 (identified by directed yeast two-hybrid). A distinct nuclear export signal (NES) that is CRM1-independent was also identified, and interspecies heterokaryon assays demonstrated that BRMS1 shuttles between nuclear and cytosolic compartments.","method":"Nuclear import/export reporter assays, directed yeast two-hybrid (importin α6 interaction), leptomycin-B treatment, interspecies heterokaryon assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vivo functional localization assays; single lab","pmids":["19649328"],"is_preprint":false},{"year":2011,"finding":"TNF-induced phosphorylation of RelA/p65 at S276 promotes direct recruitment of DNMT-1 to the BRMS1 promoter, resulting in CpG methylation and transcriptional repression of BRMS1; small-molecule inhibition of RelA/p65–DNMT-1 interaction domains abrogates BRMS1 methylation.","method":"ChIP, site-directed mutagenesis (S276), co-immunoprecipitation, methylation-specific PCR, luciferase reporter, small-molecule domain inhibition","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods including mutagenesis, ChIP, and pharmacological validation in single rigorous study","pmids":["21765477"],"is_preprint":false},{"year":2011,"finding":"BRMS1 is ubiquitinated and destabilized by the Cul3-SPOP E3 ubiquitin ligase complex; Cul3 is a direct binding partner of BRMS1 and SPOP is the adaptor protein mediating their interaction. Knockdown of SPOP increases BRMS1 protein levels and represses expression of BRMS1 target genes OPN and uPA.","method":"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, Western blot of target genes","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus ubiquitination assay plus functional target gene readout, single lab","pmids":["22085717"],"is_preprint":false},{"year":2011,"finding":"The crystal structure of BRMS1 residues 51–98 reveals an antiparallel coiled-coil motif that homo-oligomerizes as a hexamer (trimer of coiled-coil dimers) in solution, as confirmed by hydrodynamic experiments. This N-terminal coiled-coil region mediates molecular recognition relevant to partner binding and cellular localization.","method":"X-ray crystallography, hydrodynamic/biophysical experiments (sedimentation, size-exclusion chromatography)","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with corroborating biophysical validation; single lab but rigorous structural determination","pmids":["21777593"],"is_preprint":false},{"year":2012,"finding":"BRMS1 has an E3 ubiquitin ligase function: it induces polyubiquitination of the histone acetyltransferase p300, leading to proteasome-mediated degradation of p300. The evolutionarily conserved CXD motif in BRMS1 is responsible for this E3 ligase activity; mutation of this motif abolishes p300 ubiquitination/degradation and dramatically reduces BRMS1 metastasis suppressor function in vitro and in vivo.","method":"Ubiquitination assay, CXD motif mutagenesis, proteasome inhibitor experiments, in vitro and in vivo metastasis models","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Strong — novel enzymatic activity demonstrated with mutagenesis of catalytic motif plus functional metastasis readout; confirmed by independent study (PMID 25675294)","pmids":["23269275"],"is_preprint":false},{"year":2013,"finding":"NLS2 (C-terminal putative NLS, amino acids 238–244) of BRMS1 is not required for nuclear localization per se but is critical for metastasis suppression. BRMS1 and BRMS1(NLS2,2) (where NLS2 is functional) co-immunoprecipitate with SIN3A in both nucleus and cytoplasm and down-regulate miR-10b, whereas NLS1-containing variants that are nuclear-only do not suppress metastasis or down-regulate miR-10b.","method":"NLS substitution mutagenesis, xenograft metastasis model, co-immunoprecipitation, miR-10b quantification","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean mutagenesis with in vivo functional readout and mechanistic co-IP, single lab","pmids":["23390556"],"is_preprint":false},{"year":2013,"finding":"BRMS1 expression reduces activation of β1 integrin and focal adhesion kinase (FAK) and decreases their localization to focal adhesion sites, without altering integrin monomer expression levels; BRMS1-expressing cells fail to reorganize their cytoskeleton and form invasive colonies under 3D culture conditions.","method":"Time-lapse and confocal microscopy, 3D culture, immunofluorescence for β1 integrin/FAK activation","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct imaging-based localization tied to functional consequence; single lab","pmids":["24000122"],"is_preprint":false},{"year":2014,"finding":"Loss of BRMS1 promotes EMT in NSCLC cells in a manner dependent on RelA/p65 (NF-κB); ChIP analysis shows that loss of BRMS1 increases RelA/p65 K310 occupancy at the Twist1 promoter, activating Twist1 transcription. Knockdown of Twist1 reverses BRMS1-loss-mediated EMT phenotypes; double BRMS1(KD)/Twist1(KD) cells are less efficient in establishing lung tumors in vivo.","method":"shRNA knockdown, ChIP, EMT marker immunoblotting, migration assay, in vivo lung tumor model","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (double KD) with ChIP mechanistic validation and in vivo phenotype; multiple orthogonal methods in single rigorous study","pmids":["25368381"],"is_preprint":false},{"year":2015,"finding":"iASPP stabilizes p300 and CBP by interfering with BRMS1-mediated ubiquitination of these acetyltransferases; BRMS1 can rescue degradation of p300 and CBP in iASPP-depleted cells, and iASPP overexpression partially abolishes the BRMS1–CBP interaction upon DNA damage, thereby contributing to apoptotic susceptibility.","method":"shRNA depletion, co-immunoprecipitation, Western blot of p300/CBP levels, rescue assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and rescue experiments confirming BRMS1 E3 ligase activity on CBP as well as p300; single lab","pmids":["25675294"],"is_preprint":false},{"year":2016,"finding":"TNF-induced CK2α' phosphorylates nuclear BRMS1 on serine 30 (S30), triggering 14-3-3ε-mediated nuclear export, increased cytosolic BRMS1 accumulation, and subsequent ubiquitin-proteasome degradation; S30 mutation or CK2 inhibition (CX4945) abrogates this process and reduces NSCLC metastasis ~60-fold in an orthotopic mouse model.","method":"Site-directed mutagenesis (S30), co-immunoprecipitation with 14-3-3ε, CK2-specific inhibitor, subcellular fractionation, orthotopic xenograft","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — phosphorylation site mutagenesis, defined kinase, pharmacological rescue, and in vivo validation; multiple orthogonal methods","pmids":["26980766"],"is_preprint":false},{"year":2016,"finding":"BRMS1 is phosphorylated on serine 237 by CDK2; this phosphorylation does not affect cell cycle progression, nuclear localization, or mSin3/HDAC complex association or transcriptional repressor activity, but does affect cancer cell migration.","method":"In vitro kinase assay, phospho-site mutagenesis (S237), co-immunoprecipitation with mSin3, migration assay, cell cycle analysis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — kinase assay with mutagenesis and functional migration readout; single lab","pmids":["26771717"],"is_preprint":false},{"year":2018,"finding":"BRMS1 is an integral component of the LSD1/CoREST corepressor complex; affinity purification and mass spectrometry identified this interaction, and BRMS1 together with LSD1 are required for inhibition of breast cancer cell migration and invasion. RNA-seq identified target genes regulated by the BRMS1/LSD1 complex including VIM, INSIG2, KLK11, and others.","method":"Affinity purification, mass spectrometry, RNA-seq, migration/invasion assays with LSD1 knockdown","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass spectrometry-confirmed complex with functional epistasis; single lab","pmids":["30416854"],"is_preprint":false},{"year":2018,"finding":"FANCI is a novel interacting protein of BRMS1; the linker region between the two coiled-coil motifs of BRMS1 mediates the BRMS1–FANCI interaction. Knockdown or knockout of BRMS1 diminishes monoubiquitination of FANCI and FANCD2 in response to DNA interstrand crosslink (ICL) damage, suppresses FANCD2 foci formation, and causes hypersensitivity to ICL agents; rescue with BRMS1 constructs unable to bind FANCI fails to restore ICL resistance.","method":"Co-immunoprecipitation, BRMS1 deletion constructs, ubiquitination assay, FANCD2 foci immunofluorescence, ICL sensitivity assay, BRMS1 knockout","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, functional epistasis via rescue constructs, and multiple DNA damage assays; single lab","pmids":["30365131"],"is_preprint":false},{"year":2020,"finding":"TRIM7 ubiquitinates BRMS1, promoting its degradation; this is the mechanism through which TRIM7 regulates osteosarcoma cell migration and invasion. Loss of TRIM7 m6A modification (mediated by METTL3/YTHDF2) accounts for aberrant TRIM7 levels.","method":"Immunoprecipitation, mass spectrometry, ubiquitination assay, pulldown, immunofluorescence, RNA immunoprecipitation for m6A","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay with co-IP and functional migration/invasion readout; single lab","pmids":["32853985"],"is_preprint":false},{"year":2015,"finding":"JARID1C (a histone demethylase) represses BRMS1 transcription by modulating H3K4me3 levels at the BRMS1 gene promoter; JARID1C silencing dramatically increases BRMS1 expression, and BRMS1 knockdown reverses shJARID1C-induced migration inhibition.","method":"siRNA knockdown, ChIP for H3K4me3, qRT-PCR/Western blot, migration/invasion assays, rescue experiment","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for specific histone mark at BRMS1 promoter with epistasis rescue; single lab","pmids":["26182878"],"is_preprint":false},{"year":2010,"finding":"ING4 is induced by BRMS1 and functions downstream of BRMS1 to inhibit melanoma angiogenesis; ING4 suppresses NF-κB activity and IL-6 expression. Knockdown of ING4 abrogates BRMS1's suppressive effect on HUVEC growth, and ING4 overexpression blocks BRMS1 knockdown-induced angiogenesis—establishing ING4 as a downstream effector of BRMS1.","method":"siRNA/overexpression epistasis, HUVEC growth/tube formation assays, NF-κB reporter, IL-6 ELISA, in vivo matrigel plug assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with double knockdown/overexpression rescue; single lab","pmids":["21056991"],"is_preprint":false},{"year":2017,"finding":"DAPK1 is a direct transcriptional target activated by BRMS1; BRMS1 binds to NF-κB binding sites in the DAPK1 promoter (−200 to −80 bp region) as shown by ChIP, and site-directed mutation of these NF-κB sites abolishes the BRMS1-dependent transcriptional activation of DAPK1.","method":"Microarray, qRT-PCR, Western blot, luciferase promoter deletion assays, ChIP, site-directed mutagenesis of NF-κB sites","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and mutagenesis confirm direct promoter binding and functional activation; single lab","pmids":["28339067"],"is_preprint":false},{"year":2018,"finding":"BRMS1 directly binds to the SCIN (scinderin) promoter and represses its transcription; knockdown of SCIN sensitizes HCC cells to chemotherapeutic drugs and suppresses tumor growth, while SCIN overexpression protects against apoptosis.","method":"ChIP (BRMS1 at SCIN promoter), FACS apoptosis analysis, caspase-9 immunoblot, in vivo xenograft","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP evidence of promoter binding with functional apoptosis readout; single lab","pmids":["30034938"],"is_preprint":false},{"year":2022,"finding":"The BRMS1v2 A273V SNP (rs1052566) abolishes the metastasis suppressor function of BRMS1v2; mechanistically, BRMS1v2 A273V fails to interact with nuclear Src, thereby activating intratumoral c-fos, which upregulates CEACAM6 to drive metastases. Wild-type BRMS1v2 interaction with nuclear Src suppresses c-fos-mediated transcriptional regulation.","method":"Next-generation sequencing, co-immunoprecipitation (Src interaction), in vitro invasion assays, tail-vein and intracardiac PDO xenograft models, pharmacological c-fos inhibition (T5224)","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — SNP mutagenesis combined with co-IP mechanism, multiple in vivo models, and pharmacological rescue; single lab with rigorous multi-model validation","pmids":["36197962"],"is_preprint":false},{"year":2016,"finding":"BRMS1 expression restores P2Y2 purinergic receptor levels and ATP-induced cytosolic calcium mobilization in MDA-MB-435 breast cancer cells to levels comparable to non-metastatic epithelial cells, sensitizing cells to ATP-induced growth suppression.","method":"P2Y2 expression analysis, calcium mobilization assay, proliferation assay with ATP treatment","journal":"BioResearch open access","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single assay set showing receptor level restoration and calcium signaling; single lab, no mechanistic dissection of how BRMS1 regulates P2Y2","pmids":["23593560"],"is_preprint":false},{"year":2009,"finding":"BRMS1 interacts with Hsp27 in complex in MCF7 breast cancer cells, as identified by immunoprecipitation of endogenous BRMS1 complexes followed by mass spectrometry.","method":"Immunoprecipitation of endogenous BRMS1 from MCF7 cells, mass spectrometry identification","journal":"Protein expression and purification","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single immunoprecipitation/MS identification; no functional follow-up on the interaction","pmids":["19401233"],"is_preprint":false},{"year":2015,"finding":"BRMS1 attenuates TGF-β1-induced breast cancer EMT and invasion by downregulating HIF-1α transcript through inactivation of NF-κB; HIF-1α is required for TGF-β1-induced Snail and TWIST1 expression, and BRMS1 reduces both via the NF-κB/HIF-1α axis.","method":"ChIP, luciferase reporter assay, qRT-PCR, immunoblotting, Matrigel invasion assay","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assays validate NF-κB/HIF-1α/Snail-TWIST1 cascade; single lab","pmids":["26520789"],"is_preprint":false},{"year":2021,"finding":"Phosphorylation status at BRMS1 S237 regulates its protein interaction network: S237 presence is associated with interactions related to cell cycle (CDKN2A), DNA repair (BRCA1), and metastasis (TCF2, POLE2), and directly decreases MDA-MB-231 migration in vitro and metastases in vivo; the C-terminus of BRMS1 is critical for metastasis suppression.","method":"Affinity purification-mass spectrometry (AP-MS) of BRMS1 interactome with S237 mutants, in vitro migration assay, in vivo metastasis model","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative interactome with phospho-mutants plus in vivo validation; single lab","pmids":["34788285"],"is_preprint":false}],"current_model":"BRMS1 is a predominantly nuclear metastasis suppressor that functions as a component of mSin3/HDAC and LSD1/CoREST chromatin remodeling complexes to repress transcription of pro-metastatic genes (e.g., OPN, uPA, SCIN) and activate pro-apoptotic targets (DAPK1); it also possesses an intrinsic CXD-motif-dependent E3 ubiquitin ligase activity that degrades the histone acetyltransferase p300/CBP; its stability and localization are post-translationally regulated by Hsp90 chaperone stabilization, Cul3-SPOP- and TRIM7-mediated ubiquitination/degradation, and CK2α'-dependent phosphorylation at S30 that triggers 14-3-3ε-mediated nuclear export and proteasomal degradation, while CDK2-mediated phosphorylation at S237 regulates its interaction network and cell migration without affecting its chromatin complex association or nuclear localization; nuclear BRMS1 interacts with Src to suppress c-fos-dependent transcriptional programs driving metastasis, and BRMS1 also restores gap junctional intercellular communication, suppresses NF-κB activity, and participates in DNA interstrand crosslink repair by supporting FANCI/FANCD2 monoubiquitination."},"narrative":{"mechanistic_narrative":"BRMS1 is a nuclear metastasis suppressor that blocks multiple steps of the metastatic cascade — transit survival, anoikis resistance, and colonization at secondary sites — without affecting primary tumorigenicity in breast carcinoma and melanoma models [PMID:10850410, PMID:11822878, PMID:18276787]. Mechanistically it operates as a chromatin-associated transcriptional regulator: it is a stable component of the mSin3A/HDAC corepressor complex, interacting with RBP1/RBBP1 and multiple HDAC subunits to repress transcription when tethered to a promoter [PMID:14581478, PMID:15451426], and it is also an integral subunit of the LSD1/CoREST corepressor complex required for suppression of migration and invasion [PMID:30416854]. Through these activities, and by abrogating NF-κB activity, BRMS1 represses pro-metastatic genes including osteopontin and uPA [PMID:17227585, PMID:22085717] and the apoptosis-protective gene SCIN [PMID:30034938], while activating the pro-apoptotic target DAPK1 via NF-κB sites in its promoter [PMID:28339067]; loss of BRMS1 conversely de-represses RelA/p65-driven Twist1 transcription to promote EMT [PMID:25368381]. Independent of its corepressor role, BRMS1 possesses an intrinsic, CXD-motif-dependent E3 ubiquitin ligase activity that polyubiquitinates and degrades the acetyltransferases p300 and CBP, an activity essential for its metastasis-suppressor function [PMID:23269275, PMID:25675294]. BRMS1 abundance and localization are tightly controlled post-translationally: it is stabilized by Hsp90 [PMID:16919237], targeted for degradation by the Cul3-SPOP and TRIM7 ubiquitin ligases [PMID:22085717, PMID:32853985], and exported from the nucleus and degraded following CK2α'-mediated S30 phosphorylation and 14-3-3ε binding in response to TNF [PMID:26980766]. Its transcription is silenced epigenetically through NF-κB/DNMT-1-mediated promoter methylation and JARID1C-mediated H3K4me3 modulation [PMID:21765477, PMID:26182878]. Beyond gene regulation, BRMS1 supports DNA interstrand crosslink repair by promoting FANCI/FANCD2 monoubiquitination through a direct FANCI interaction [PMID:30365131], and a metastasis-suppressing splice variant interacts with nuclear Src to restrain c-fos-driven transcriptional programs [PMID:36197962].","teleology":[{"year":2000,"claim":"Established BRMS1 as a bona fide metastasis suppressor by showing it blocks dissemination without blocking primary tumor growth, defining the central question of how a single gene selectively controls metastasis.","evidence":"Differential display and stable BRMS1 transfection into MDA-MB-435/231 breast carcinoma cells in orthotopic xenografts; GJIC and motility assays","pmids":["10850410","11827072"],"confidence":"High","gaps":["Molecular effectors of suppression not identified","Mechanism of gap junction restoration unknown"]},{"year":2002,"claim":"Generalized BRMS1 suppressor activity beyond breast cancer, showing the same metastasis-selective phenotype and GJIC restoration in melanoma.","evidence":"Stable transfection and orthotopic xenograft in MelJuSo and C8161.9 melanoma lines, collagen sandwich invasion assays","pmids":["11822878"],"confidence":"Medium","gaps":["No molecular mechanism dissected","Single lab"]},{"year":2004,"claim":"Defined the molecular basis of BRMS1 transcriptional repression by placing it within the mSin3A/HDAC corepressor complex, explaining how it silences target genes.","evidence":"Yeast two-hybrid, co-IP, biochemical purification, HDAC enzymatic assays, and Gal4 reporter repression","pmids":["14581478","15451426"],"confidence":"High","gaps":["Direct target genes not yet identified","Whether repression alone explains metastasis suppression unresolved"]},{"year":2007,"claim":"Connected BRMS1's corepressor activity to a specific pro-metastatic gene, showing it suppresses osteopontin by abrogating NF-κB at the promoter.","evidence":"Luciferase OPN promoter deletions, EMSA, and ChIP with HDAC3","pmids":["17227585"],"confidence":"Medium","gaps":["Direct vs indirect NF-κB inhibition not fully resolved","Single target gene"]},{"year":2008,"claim":"Resolved which steps of the metastatic cascade BRMS1 blocks, showing it reduces transit survival and colonization and increases anoikis susceptibility.","evidence":"Cardiac injection xenografts with quantitative imaging and poly-HEMA anoikis assays","pmids":["18276787"],"confidence":"Medium","gaps":["Molecular link between transcriptional role and anoikis sensitivity not defined"]},{"year":2009,"claim":"Defined the nucleocytoplasmic trafficking of BRMS1, identifying an importin-α6-dependent NLS and a CRM1-independent NES, establishing it as a shuttling protein.","evidence":"Import/export reporter assays, directed Y2H, leptomycin-B, heterokaryon assays","pmids":["19649328"],"confidence":"Medium","gaps":["Functional consequence of shuttling not yet linked to suppression","Export receptor identity unknown"]},{"year":2011,"claim":"Established post-translational control of BRMS1 abundance via Cul3-SPOP ubiquitination and transcriptional silencing via NF-κB/DNMT-1 promoter methylation, plus a structural basis for oligomerization.","evidence":"Co-IP/ubiquitination assays with SPOP knockdown; ChIP and methylation-specific PCR with RelA S276 mutagenesis; X-ray crystallography of residues 51-98","pmids":["22085717","21765477","21777593"],"confidence":"High","gaps":["Interplay between degradation and methylation pathways not integrated","Functional role of hexameric coiled-coil oligomerization in vivo untested"]},{"year":2012,"claim":"Revealed an unexpected enzymatic function — intrinsic CXD-motif E3 ligase activity degrading p300 — required for metastasis suppression, distinguishing it from passive corepression.","evidence":"Ubiquitination assays, CXD motif mutagenesis, proteasome inhibition, and in vivo metastasis models","pmids":["23269275"],"confidence":"High","gaps":["Structural basis of ligase activity unresolved","Full substrate repertoire beyond p300/CBP unknown"]},{"year":2013,"claim":"Dissociated nuclear localization from function, showing the C-terminal NLS2 region and SIN3A co-localization (not mere nuclear residence) and miR-10b downregulation are required for suppression.","evidence":"NLS substitution mutagenesis, xenograft metastasis, co-IP with SIN3A, miR-10b quantification; integrin/FAK imaging in 3D culture","pmids":["23390556","24000122"],"confidence":"Medium","gaps":["Mechanism linking BRMS1 to miR-10b not defined","How BRMS1 reduces integrin/FAK activation unknown"]},{"year":2014,"claim":"Established the EMT axis of BRMS1 loss, showing it restrains RelA/p65-driven Twist1 transcription via promoter occupancy.","evidence":"shRNA knockdown, ChIP at Twist1 promoter, double BRMS1/Twist1 knockdown epistasis, in vivo lung tumor model","pmids":["25368381"],"confidence":"High","gaps":["Whether BRMS1 acts directly at Twist1 or via global NF-κB suppression unresolved"]},{"year":2015,"claim":"Extended the E3 ligase activity to CBP and identified iASPP as an antagonist, and mapped additional NF-κB-dependent suppression of HIF-1α/EMT and JARID1C-mediated epigenetic silencing of BRMS1.","evidence":"shRNA depletion and rescue co-IP for iASPP/CBP; ChIP/reporter for NF-κB/HIF-1α/Snail-TWIST1; ChIP for H3K4me3 at BRMS1 promoter","pmids":["25675294","26520789","26182878"],"confidence":"Medium","gaps":["Quantitative balance of competing ligase/antagonist interactions unclear","Multiple converging pathways not integrated mechanistically"]},{"year":2016,"claim":"Defined kinase-driven regulation: TNF/CK2α' phosphorylation at S30 drives 14-3-3ε-mediated export and degradation, while CDK2 phosphorylation at S237 selectively tunes migration without altering corepressor activity.","evidence":"Phospho-site mutagenesis (S30, S237), kinase assays, CK2 inhibitor CX4945, 14-3-3ε co-IP, fractionation, migration and orthotopic models","pmids":["26980766","26771717"],"confidence":"High","gaps":["How S237 phosphorylation alters the interaction network mechanistically incomplete at this stage","Crosstalk between phosphorylation and ubiquitination pathways unmapped"]},{"year":2017,"claim":"Identified DAPK1 as a directly BRMS1-activated pro-apoptotic target, showing BRMS1 can also positively regulate transcription via NF-κB sites.","evidence":"Microarray, luciferase promoter deletions, ChIP, and NF-κB site mutagenesis in the DAPK1 promoter","pmids":["28339067"],"confidence":"Medium","gaps":["How BRMS1 switches from repressor to activator at NF-κB sites unexplained"]},{"year":2018,"claim":"Broadened BRMS1's chromatin partnerships to the LSD1/CoREST complex, identified the SCIN promoter as a repressed apoptosis-protective target, and revealed a non-transcriptional role in FANCI/FANCD2-dependent ICL repair.","evidence":"Affinity purification-MS and RNA-seq with LSD1 knockdown; ChIP at SCIN promoter with apoptosis assays; co-IP and FANCD2 foci/ICL sensitivity assays with BRMS1 knockout and binding-dead rescue","pmids":["30416854","30034938","30365131"],"confidence":"Medium","gaps":["Relationship between mSin3 and LSD1/CoREST complex membership not resolved","Mechanism by which BRMS1 supports FANCI/FANCD2 monoubiquitination unknown"]},{"year":2020,"claim":"Added a second degradative ligase, TRIM7, and linked its m6A regulation to BRMS1 turnover in osteosarcoma, expanding the post-translational control network.","evidence":"IP-MS, ubiquitination assays, pulldown, and m6A RIP with METTL3/YTHDF2","pmids":["32853985"],"confidence":"Medium","gaps":["Tissue-specificity of SPOP vs TRIM7 control unresolved"]},{"year":2022,"claim":"Connected a clinically relevant SNP to a discrete mechanism: BRMS1v2 A273V loses nuclear Src binding, de-repressing c-fos and CEACAM6 to drive metastasis.","evidence":"NGS, co-IP for Src interaction, invasion assays, tail-vein/intracardiac PDO xenografts, and c-fos inhibition (T5224)","pmids":["36197962"],"confidence":"High","gaps":["How nuclear Src binding mechanistically restrains c-fos transcription not fully defined","Generalizability across cancer types untested"]},{"year":null,"claim":"How BRMS1's distinct activities — corepressor membership, intrinsic E3 ligase activity, DNA-repair support, and nuclear Src signaling — are coordinated and which dominates metastasis suppression in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating chromatin, ubiquitination, and repair roles","Endogenous structural organization of BRMS1 within its complexes unknown","Substrate selectivity of the BRMS1 E3 ligase undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,4,6,24,25]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[12,16]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[12,16]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,19]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,8,13,17]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[8,13,17]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,6,15,24,25]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[2,4,19,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,3,26]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[10,12,17,21]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[20]}],"complexes":["mSin3A/HDAC corepressor complex","LSD1/CoREST corepressor complex"],"partners":["SIN3A","RBBP1","HDAC1","LSD1","SPOP","TRIM7","FANCI","EP300"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9HCU9","full_name":"Breast cancer metastasis-suppressor 1","aliases":[],"length_aa":246,"mass_kda":28.5,"function":"Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9HCU9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BRMS1","classification":"Not Classified","n_dependent_lines":309,"n_total_lines":1208,"dependency_fraction":0.25579470198675497},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BRMS1","total_profiled":1310},"omim":[{"mim_id":"618514","title":"BRMS1-LIKE TRANSCRIPTIONAL REPRESSOR; BRMS1L","url":"https://www.omim.org/entry/618514"},{"mim_id":"606259","title":"BRMS1 TRANSCRIPTIONAL REPRESSOR AND ANOIKIS REGULATOR; BRMS1","url":"https://www.omim.org/entry/606259"},{"mim_id":"604215","title":"INHIBITOR OF GROWTH 2; ING2","url":"https://www.omim.org/entry/604215"},{"mim_id":"603300","title":"TUMOR NECROSIS FACTOR-ALPHA-INDUCED PROTEIN 2; TNFAIP2","url":"https://www.omim.org/entry/603300"},{"mim_id":"602180","title":"SIGNAL-INDUCED PROLIFERATION-ASSOCIATED GENE 1; SIPA1","url":"https://www.omim.org/entry/602180"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Centrosome","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRMS1"},"hgnc":{"alias_symbol":["DKFZP564A063"],"prev_symbol":[]},"alphafold":{"accession":"Q9HCU9","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HCU9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HCU9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HCU9-F1-predicted_aligned_error_v6.png","plddt_mean":78.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRMS1","jax_strain_url":"https://www.jax.org/strain/search?query=BRMS1"},"sequence":{"accession":"Q9HCU9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9HCU9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9HCU9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HCU9"}},"corpus_meta":[{"pmid":"10850410","id":"PMC_10850410","title":"Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10850410","citation_count":234,"is_preprint":false},{"pmid":"14581478","id":"PMC_14581478","title":"Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14581478","citation_count":142,"is_preprint":false},{"pmid":"11822878","id":"PMC_11822878","title":"Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1.","date":"2002","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/11822878","citation_count":124,"is_preprint":false},{"pmid":"17227585","id":"PMC_17227585","title":"Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation.","date":"2007","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17227585","citation_count":105,"is_preprint":false},{"pmid":"32853985","id":"PMC_32853985","title":"N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/32853985","citation_count":97,"is_preprint":false},{"pmid":"11751410","id":"PMC_11751410","title":"Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11751410","citation_count":93,"is_preprint":false},{"pmid":"18276787","id":"PMC_18276787","title":"BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process.","date":"2008","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18276787","citation_count":89,"is_preprint":false},{"pmid":"16681721","id":"PMC_16681721","title":"Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1.","date":"2006","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/16681721","citation_count":88,"is_preprint":false},{"pmid":"11827072","id":"PMC_11827072","title":"Analysis of mechanisms underlying BRMS1 suppression of metastasis.","date":"2000","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/11827072","citation_count":86,"is_preprint":false},{"pmid":"21765477","id":"PMC_21765477","title":"Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21765477","citation_count":80,"is_preprint":false},{"pmid":"19111386","id":"PMC_19111386","title":"Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19111386","citation_count":72,"is_preprint":false},{"pmid":"15451426","id":"PMC_15451426","title":"Identification of a novel BRMS1-homologue protein p40 as a component of the mSin3A/p33(ING1b)/HDAC1 deacetylase complex.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15451426","citation_count":60,"is_preprint":false},{"pmid":"16919237","id":"PMC_16919237","title":"Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16919237","citation_count":59,"is_preprint":false},{"pmid":"18566899","id":"PMC_18566899","title":"Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.","date":"2008","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/18566899","citation_count":50,"is_preprint":false},{"pmid":"22085717","id":"PMC_22085717","title":"Breast cancer metastasis suppressor 1 (BRMS1) is destabilized by the Cul3-SPOP E3 ubiquitin ligase complex.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22085717","citation_count":49,"is_preprint":false},{"pmid":"21056991","id":"PMC_21056991","title":"Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21056991","citation_count":46,"is_preprint":false},{"pmid":"15168732","id":"PMC_15168732","title":"Identification of metastasis-associated proteins through protein analysis of metastatic MDA-MB-435 and metastasis-suppressed BRMS1 transfected-MDA-MB-435 cells.","date":"2004","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/15168732","citation_count":44,"is_preprint":false},{"pmid":"20083343","id":"PMC_20083343","title":"BRMS1 expression alters the ultrastructural, biomechanical and biochemical properties of MDA-MB-435 human breast carcinoma cells: an AFM and Raman microspectroscopy study.","date":"2010","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/20083343","citation_count":37,"is_preprint":false},{"pmid":"21827753","id":"PMC_21827753","title":"Unraveling the enigmatic complexities of BRMS1-mediated metastasis suppression.","date":"2011","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/21827753","citation_count":36,"is_preprint":false},{"pmid":"20455258","id":"PMC_20455258","title":"BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathological stage in non-small cell lung cancer.","date":"2010","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20455258","citation_count":36,"is_preprint":false},{"pmid":"11774238","id":"PMC_11774238","title":"Identification and characterization of the murine ortholog (brms1) of breast-cancer metastasis suppressor 1 (BRMS1).","date":"2002","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11774238","citation_count":36,"is_preprint":false},{"pmid":"17854218","id":"PMC_17854218","title":"Proteomics-based strategy to delineate the molecular mechanisms of the metastasis suppressor gene BRMS1.","date":"2007","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/17854218","citation_count":36,"is_preprint":false},{"pmid":"26182878","id":"PMC_26182878","title":"Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26182878","citation_count":35,"is_preprint":false},{"pmid":"25368381","id":"PMC_25368381","title":"Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of Twist1.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25368381","citation_count":34,"is_preprint":false},{"pmid":"29552146","id":"PMC_29552146","title":"MicroRNA-125a-5p inhibits invasion and metastasis of gastric cancer cells by targeting BRMS1 expression.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29552146","citation_count":33,"is_preprint":false},{"pmid":"18543067","id":"PMC_18543067","title":"BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation.","date":"2008","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/18543067","citation_count":33,"is_preprint":false},{"pmid":"23269275","id":"PMC_23269275","title":"BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/23269275","citation_count":32,"is_preprint":false},{"pmid":"26980766","id":"PMC_26980766","title":"CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26980766","citation_count":30,"is_preprint":false},{"pmid":"18841483","id":"PMC_18841483","title":"Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model.","date":"2008","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/18841483","citation_count":29,"is_preprint":false},{"pmid":"16006775","id":"PMC_16006775","title":"Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes.","date":"2005","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16006775","citation_count":28,"is_preprint":false},{"pmid":"27501413","id":"PMC_27501413","title":"miR-346 promotes migration and invasion of nasopharyngeal carcinoma cells via targeting BRMS1.","date":"2016","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/27501413","citation_count":28,"is_preprint":false},{"pmid":"30416854","id":"PMC_30416854","title":"BRMS1 coordinates with LSD1 and suppresses breast cancer cell metastasis.","date":"2018","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30416854","citation_count":25,"is_preprint":false},{"pmid":"29312509","id":"PMC_29312509","title":"MicroRNA-423 enhances the invasiveness of hepatocellular carcinoma via regulation of BRMS1.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/29312509","citation_count":25,"is_preprint":false},{"pmid":"15978719","id":"PMC_15978719","title":"Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (Brms1).","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15978719","citation_count":24,"is_preprint":false},{"pmid":"24879377","id":"PMC_24879377","title":"BRMS1 suppresses glioma progression by regulating invasion, migration and adhesion of glioma cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24879377","citation_count":22,"is_preprint":false},{"pmid":"29890825","id":"PMC_29890825","title":"MicroRNA-3200-5p Promotes Osteosarcoma Cell Invasion via Suppression of BRMS1.","date":"2018","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/29890825","citation_count":21,"is_preprint":false},{"pmid":"26617826","id":"PMC_26617826","title":"Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26617826","citation_count":21,"is_preprint":false},{"pmid":"32232621","id":"PMC_32232621","title":"BRMS1: a multifunctional signaling molecule in metastasis.","date":"2020","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32232621","citation_count":20,"is_preprint":false},{"pmid":"19649328","id":"PMC_19649328","title":"Identification of essential sequences for cellular localization in BRMS1 metastasis suppressor.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19649328","citation_count":20,"is_preprint":false},{"pmid":"22678236","id":"PMC_22678236","title":"Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes.","date":"2012","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22678236","citation_count":19,"is_preprint":false},{"pmid":"26328523","id":"PMC_26328523","title":"Breast carcinoma metastasis suppressor gene 1 (BRMS1): update on its role as the suppressor of cancer metastases.","date":"2015","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26328523","citation_count":19,"is_preprint":false},{"pmid":"22931099","id":"PMC_22931099","title":"Low BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survival.","date":"2012","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22931099","citation_count":19,"is_preprint":false},{"pmid":"19070953","id":"PMC_19070953","title":"Over-expression of the BRMS1 family member SUDS3 does not suppress metastasis of human cancer cells.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19070953","citation_count":19,"is_preprint":false},{"pmid":"26520789","id":"PMC_26520789","title":"Breast cancer metastasis suppressor 1 (BRMS1) attenuates TGF-β1-induced breast cancer cell aggressiveness through downregulating HIF-1α expression.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26520789","citation_count":18,"is_preprint":false},{"pmid":"24000122","id":"PMC_24000122","title":"Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix.","date":"2013","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24000122","citation_count":18,"is_preprint":false},{"pmid":"23390556","id":"PMC_23390556","title":"The C-terminal putative nuclear localization sequence of breast cancer metastasis suppressor 1, BRMS1, is necessary for metastasis suppression.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23390556","citation_count":17,"is_preprint":false},{"pmid":"36197962","id":"PMC_36197962","title":"A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting c-fos.","date":"2022","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36197962","citation_count":17,"is_preprint":false},{"pmid":"25182004","id":"PMC_25182004","title":"BRMS1 regulates apoptosis in non-small cell lung cancer cells.","date":"2015","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/25182004","citation_count":15,"is_preprint":false},{"pmid":"27140445","id":"PMC_27140445","title":"Cancer-specific promoters for expression-targeted gene therapy: ran, brms1 and mcm5.","date":"2016","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27140445","citation_count":14,"is_preprint":false},{"pmid":"22241150","id":"PMC_22241150","title":"Ubiquitous Brms1 expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis.","date":"2012","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/22241150","citation_count":14,"is_preprint":false},{"pmid":"26544623","id":"PMC_26544623","title":"Cullin3 promotes breast cancer cells metastasis and epithelial-mesenchymal transition by targeting BRMS1 for degradation.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26544623","citation_count":14,"is_preprint":false},{"pmid":"25675294","id":"PMC_25675294","title":"A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25675294","citation_count":14,"is_preprint":false},{"pmid":"26771717","id":"PMC_26771717","title":"Cyclin-dependent kinase-mediated phosphorylation of breast cancer metastasis suppressor 1 (BRMS1) affects cell migration.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/26771717","citation_count":13,"is_preprint":false},{"pmid":"24984534","id":"PMC_24984534","title":"BRMS1 inhibits expression of NF-kappaB subunit p65, uPA and OPN in ovarian cancer cells.","date":"2014","source":"European journal of gynaecological oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24984534","citation_count":13,"is_preprint":false},{"pmid":"24596389","id":"PMC_24596389","title":"Expression of breast cancer metastasis suppressor-1, BRMS-1, in human breast cancer and the biological impact of BRMS-1 on the migration of breast cancer cells.","date":"2014","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24596389","citation_count":13,"is_preprint":false},{"pmid":"24748145","id":"PMC_24748145","title":"Effect of BRMS1 on tumorigenicity and metastasis of human rectal cancer.","date":"2014","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/24748145","citation_count":12,"is_preprint":false},{"pmid":"19307053","id":"PMC_19307053","title":"Expression of the Breast Cancer Metastasis Suppressor 1 (BRMS1) maintains in vitro chemosensitivity of breast cancer cells.","date":"2009","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19307053","citation_count":12,"is_preprint":false},{"pmid":"36061794","id":"PMC_36061794","title":"Defect in BrMS1, a PHD-finger transcription factor, induces male sterility in ethyl methane sulfonate-mutagenized Chinese cabbage (Brassica rapa L. ssp. pekinensis).","date":"2022","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/36061794","citation_count":11,"is_preprint":false},{"pmid":"21777593","id":"PMC_21777593","title":"The structure of BRMS1 nuclear export signal and SNX6 interacting region reveals a hexamer formed by antiparallel coiled coils.","date":"2011","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21777593","citation_count":11,"is_preprint":false},{"pmid":"28121354","id":"PMC_28121354","title":"Breast cancer metastasis suppressor 1 (BRMS1) suppresses prostate cancer progression by inducing apoptosis and regulating invasion.","date":"2017","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28121354","citation_count":11,"is_preprint":false},{"pmid":"22356729","id":"PMC_22356729","title":"Location, location, location: the BRMS1 protein and melanoma progression.","date":"2012","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22356729","citation_count":10,"is_preprint":false},{"pmid":"31571904","id":"PMC_31571904","title":"Epigenetics mechanisms mediate the miR-125a/BRMS1 axis to regulate invasion and metastasis in gastric cancer.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31571904","citation_count":10,"is_preprint":false},{"pmid":"23643861","id":"PMC_23643861","title":"Cloning and characterization of a novel human BRMS1 transcript variant in hepatocellular carcinoma cells.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23643861","citation_count":10,"is_preprint":false},{"pmid":"31628639","id":"PMC_31628639","title":"MiR-147 inhibits cyclic mechanical stretch-induced apoptosis in L6 myoblasts via ameliorating endoplasmic reticulum stress by targeting BRMS1.","date":"2019","source":"Cell stress & chaperones","url":"https://pubmed.ncbi.nlm.nih.gov/31628639","citation_count":10,"is_preprint":false},{"pmid":"23771732","id":"PMC_23771732","title":"Case-only analyses of the associations between polymorphisms in the metastasis-modifying genes BRMS1 and SIPA1 and breast tumor characteristics, lymph node metastasis, and survival.","date":"2013","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/23771732","citation_count":10,"is_preprint":false},{"pmid":"30034938","id":"PMC_30034938","title":"Scinderin is a novel transcriptional target of BRMS1 involved in regulation of hepatocellular carcinoma cell apoptosis.","date":"2018","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30034938","citation_count":10,"is_preprint":false},{"pmid":"27613131","id":"PMC_27613131","title":"Breast Cancer Metastasis Suppressor 1 (BRMS1): Robust Biological and Pathological Data, But Still Enigmatic Mechanism of Action.","date":"2016","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27613131","citation_count":10,"is_preprint":false},{"pmid":"21355308","id":"PMC_21355308","title":"[Expression of SATB1 and BRMS1 in ovarian serous adenocarcinoma and its relationship with clinieopathological features].","date":"2011","source":"Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","url":"https://pubmed.ncbi.nlm.nih.gov/21355308","citation_count":9,"is_preprint":false},{"pmid":"24688598","id":"PMC_24688598","title":"Expression of the metastasis suppressor BRMS1 in uveal melanoma.","date":"2014","source":"Ecancermedicalscience","url":"https://pubmed.ncbi.nlm.nih.gov/24688598","citation_count":8,"is_preprint":false},{"pmid":"34054958","id":"PMC_34054958","title":"Long Noncoding RNA HCG11 Acts as a Tumor Suppressor in Gastric Cancer by Regulating miR-942-5p/BRMS1 Axis.","date":"2021","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34054958","citation_count":8,"is_preprint":false},{"pmid":"21737612","id":"PMC_21737612","title":"mRNA expression of the putative antimetastatic gene BRMS1 and of apoptosis-related genes in breast cancer.","date":"2011","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/21737612","citation_count":7,"is_preprint":false},{"pmid":"24260596","id":"PMC_24260596","title":"Effect and mechanism of the metastasis suppressor gene BRMS1 on the migration of breast cancer cells.","date":"2013","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24260596","citation_count":7,"is_preprint":false},{"pmid":"35449111","id":"PMC_35449111","title":"microRNA-15b-5p encapsulated by M2 macrophage-derived extracellular vesicles promotes gastric cancer metastasis by targeting BRMS1 and suppressing DAPK1 transcription.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35449111","citation_count":7,"is_preprint":false},{"pmid":"19401233","id":"PMC_19401233","title":"Purification and characterisation of the breast cancer metastasis suppressor, BRMS1.","date":"2009","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/19401233","citation_count":6,"is_preprint":false},{"pmid":"26433658","id":"PMC_26433658","title":"Effect of BRMS1 expression on proliferation, migration and adhesion of mouse forestomach carcinoma.","date":"2015","source":"Asian Pacific journal of tropical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26433658","citation_count":6,"is_preprint":false},{"pmid":"29275584","id":"PMC_29275584","title":"[DNA methylation modification of BRMS1 in triple-negative breast cancer and its correlation with tumor metastasis].","date":"2017","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/29275584","citation_count":5,"is_preprint":false},{"pmid":"31233204","id":"PMC_31233204","title":"Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway.","date":"2019","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/31233204","citation_count":5,"is_preprint":false},{"pmid":"30365131","id":"PMC_30365131","title":"BRMS1 participates in regulating cell sensitivity to DNA interstrand crosslink damage by interacting with FANCI.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30365131","citation_count":4,"is_preprint":false},{"pmid":"26821020","id":"PMC_26821020","title":"ERα Mediates Estrogen-Induced Expression of the Breast Cancer Metastasis Suppressor Gene BRMS1.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26821020","citation_count":4,"is_preprint":false},{"pmid":"23593560","id":"PMC_23593560","title":"BRMS1 Sensitizes Breast Cancer Cells to ATP-Induced Growth Suppression.","date":"2013","source":"BioResearch open access","url":"https://pubmed.ncbi.nlm.nih.gov/23593560","citation_count":4,"is_preprint":false},{"pmid":"34788285","id":"PMC_34788285","title":"Perturbation of BRMS1 interactome reveals pathways that impact metastasis.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34788285","citation_count":4,"is_preprint":false},{"pmid":"37296870","id":"PMC_37296870","title":"BRMS1 in Gliomas-An Expression Analysis.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37296870","citation_count":3,"is_preprint":false},{"pmid":"28339067","id":"PMC_28339067","title":"Characterization of DAPK1 as a novel transcriptional target of BRMS1.","date":"2017","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28339067","citation_count":3,"is_preprint":false},{"pmid":"19621595","id":"PMC_19621595","title":"[Expression of gene BRMS1 and CD44v6 protein in supraglottic laryngeal carcinoma and its clinical significance].","date":"2009","source":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/19621595","citation_count":3,"is_preprint":false},{"pmid":"39396919","id":"PMC_39396919","title":"Anti-metastatic Effects of Bee Venom and Melittin in Breast Cancer Cells by Upregulation of BRMS1 and DRG1 Genes.","date":"2024","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/39396919","citation_count":3,"is_preprint":false},{"pmid":"32405371","id":"PMC_32405371","title":"Metastasis inhibition by BRMS1 and miR-31 replacement therapy in claudin-low cell lines.","date":"2020","source":"Iranian journal of basic medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32405371","citation_count":3,"is_preprint":false},{"pmid":"34096224","id":"PMC_34096224","title":"Metastasis Inhibition by Cell Type Specific Expression of BRMS1 Gene under The Regulation of miR200 Family Response Elements.","date":"2021","source":"Cell journal","url":"https://pubmed.ncbi.nlm.nih.gov/34096224","citation_count":3,"is_preprint":false},{"pmid":"32742405","id":"PMC_32742405","title":"Anti-tumor peptide SA12 inhibits metastasis of MDA-MB-231 and MCF-7 breast cancer cells via increasing expression of the tumor metastasis suppressor genes, CDH1, nm23-H1 and BRMS1.","date":"2020","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32742405","citation_count":3,"is_preprint":false},{"pmid":"22239051","id":"PMC_22239051","title":"[Expression of BRMS1 gene protein in nasal and paranasal sinus carcinomas].","date":"2011","source":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/22239051","citation_count":3,"is_preprint":false},{"pmid":"40106959","id":"PMC_40106959","title":"Estradiol conjugation to estrogen receptorα upregulates Brms1 expression mediating M2 polarization of alveolar macrophages and exacerbating airway inflammation in asthmatic mice.","date":"2025","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40106959","citation_count":1,"is_preprint":false},{"pmid":"16963426","id":"PMC_16963426","title":"[Progress on breast cancer metastasis suppressor 1 (BRMS1)].","date":"2006","source":"Yi chuan = Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/16963426","citation_count":1,"is_preprint":false},{"pmid":"40665664","id":"PMC_40665664","title":"BRMS1 suppresses the PI3K/AKT/mTOR pathway to regulate autophagy in multiple myeloma.","date":"2025","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/40665664","citation_count":0,"is_preprint":false},{"pmid":"42082997","id":"PMC_42082997","title":"A sponge homolog of BRMS1 reveals ancient origin of metastasis-suppressing functions.","date":"2026","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/42082997","citation_count":0,"is_preprint":false},{"pmid":"23167184","id":"PMC_23167184","title":"[The study of expression of BRMS1 gene protein and the expression of BRMS1 gene promotor area methylation in supraglottic laryngeal carcinoma and its clinical significance].","date":"2012","source":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/23167184","citation_count":0,"is_preprint":false},{"pmid":"31394646","id":"PMC_31394646","title":"Down-regulation of BRMS1 mRNA Expression in Breast Cancer is not Related to the Presence of Axillary Node Metastasis.","date":"2005","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/31394646","citation_count":0,"is_preprint":false},{"pmid":"39660332","id":"PMC_39660332","title":"Erratum: Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.","date":"2024","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/39660332","citation_count":0,"is_preprint":false},{"pmid":"25187687","id":"PMC_25187687","title":"Modelling and simulation of mutant alleles of breast cancer metastasis suppressor 1 (BRMS1) gene.","date":"2014","source":"Bioinformation","url":"https://pubmed.ncbi.nlm.nih.gov/25187687","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47088,"output_tokens":7759,"usd":0.128825,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17128,"output_tokens":5382,"usd":0.110095,"stage2_stop_reason":"end_turn"},"total_usd":0.23892,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"BRMS1 was identified as a novel metastasis suppressor gene encoded on chromosome 11q13.1-q13.2; stable transfection of BRMS1 cDNA into MDA-MB-435 and MDA-MB-231 breast carcinoma cells significantly suppressed metastasis to lungs and regional lymph nodes without inhibiting tumorigenicity.\",\n      \"method\": \"Differential display, stable transfection, orthotopic xenograft mouse model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean loss/gain-of-function in two cell lines with defined in vivo metastatic phenotype, independently replicated across multiple subsequent studies\",\n      \"pmids\": [\"10850410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BRMS1 re-expression restored homotypic gap junctional intercellular communication (GJIC) in human breast carcinoma cells, and modestly inhibited motility (~30–60%) and soft-agar growth in MDA-MB-435; no consistent effects on adhesion to ECM components, MMP/heparanase expression, invasion, or upregulation of other metastasis suppressors (NM23, KAI1, KiSS1, E-cadherin) were detected.\",\n      \"method\": \"Gap junction assay, motility assay, soft-agar colony formation, adhesion assays, RT-PCR\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro assays in single lab; gap junction restoration replicated in subsequent work\",\n      \"pmids\": [\"11827072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BRMS1 interacts with retinoblastoma-binding protein 1 (RBP1/RBBP1) and at least seven members of the mSin3 histone deacetylase (HDAC) complex; it co-immunoprecipitates enzymatically active HDAC proteins and represses transcription when tethered to a Gal4 promoter in vivo. BRMS1 exists in large mSin3 complexes (~1.4–1.9 MDa) and in smaller HDAC1-containing complexes. The C-terminal 42 amino acids are not critical for interaction with most of the mSin3 complex.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, HDAC enzymatic assay, Gal4-reporter transcription repression assay, deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (Y2H, co-IP, enzymatic activity, reporter assay), replicated by multiple subsequent studies\",\n      \"pmids\": [\"14581478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BRMS1 suppresses metastasis (but not tumorigenicity) in human melanoma cell lines MelJuSo and C8161.9 in vivo, and restores homotypic gap junctional intercellular communication and reduces invasion in collagen sandwich assays in these cells.\",\n      \"method\": \"Stable transfection, orthotopic xenograft, collagen sandwich invasion assay, GJIC assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean gain-of-function with defined in vivo phenotype in two melanoma cell lines, single lab\",\n      \"pmids\": [\"11822878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BRMS1 was identified as a component of the mSin3A/HDAC1 complex alongside RBP1 and p33(ING1b); a BRMS1-homologue, p40 (also homologous to yeast Sds3 and mammalian mSds3), was biochemically purified from this complex and the associated complex showed strong HDAC activity.\",\n      \"method\": \"Biochemical purification, mass spectrometry, HDAC activity assay, Gal4 transcription repression reporter\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — biochemical purification with enzymatic activity confirmation in single lab\",\n      \"pmids\": [\"15451426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BRMS1 is stabilized by the Hsp90 chaperone and its turnover is proteasome-dependent; BRMS1 interacts with chaperones DNAJB6 (MRJ), Hsp90, and Hsp70, as well as with class II HDACs 4, 5, and 6, in addition to core mSin3 complex components.\",\n      \"method\": \"Yeast two-hybrid, immuno-affinity chromatography, co-immunoprecipitation, proteasome inhibitor experiments\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and biochemical validation, single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"16919237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BRMS1 inhibits osteopontin (OPN) transcription by abrogating NF-κB activation at a specific NF-κB binding site in the OPN promoter; HDAC3 participates in suppression of OPN via this NF-κB site.\",\n      \"method\": \"Luciferase reporter assays with OPN promoter deletions, EMSA, chromatin immunoprecipitation (ChIP)\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and EMSA confirm NF-κB binding site, luciferase reporters validate functional suppression; single lab\",\n      \"pmids\": [\"17227585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BRMS1 inhibits multiple steps of the metastatic cascade: fewer BRMS1-expressing cells reach the lungs or bone after intravascular injection (suggesting increased cell death in transit), and most cells reaching secondary sites fail to proliferate (inhibition of colonization); BRMS1 expression also increases susceptibility to anoikis in vitro.\",\n      \"method\": \"Cardiac ventricle injection xenograft model, quantitative in vivo imaging, poly-HEMA anoikis assay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo model with direct quantification of metastatic steps plus corroborating in vitro anoikis assay; single lab\",\n      \"pmids\": [\"18276787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BRMS1 contains one functional nuclear localization signal (NLS) that is necessary and sufficient for nuclear import, mediated specifically by importin α6 (identified by directed yeast two-hybrid). A distinct nuclear export signal (NES) that is CRM1-independent was also identified, and interspecies heterokaryon assays demonstrated that BRMS1 shuttles between nuclear and cytosolic compartments.\",\n      \"method\": \"Nuclear import/export reporter assays, directed yeast two-hybrid (importin α6 interaction), leptomycin-B treatment, interspecies heterokaryon assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vivo functional localization assays; single lab\",\n      \"pmids\": [\"19649328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TNF-induced phosphorylation of RelA/p65 at S276 promotes direct recruitment of DNMT-1 to the BRMS1 promoter, resulting in CpG methylation and transcriptional repression of BRMS1; small-molecule inhibition of RelA/p65–DNMT-1 interaction domains abrogates BRMS1 methylation.\",\n      \"method\": \"ChIP, site-directed mutagenesis (S276), co-immunoprecipitation, methylation-specific PCR, luciferase reporter, small-molecule domain inhibition\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods including mutagenesis, ChIP, and pharmacological validation in single rigorous study\",\n      \"pmids\": [\"21765477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BRMS1 is ubiquitinated and destabilized by the Cul3-SPOP E3 ubiquitin ligase complex; Cul3 is a direct binding partner of BRMS1 and SPOP is the adaptor protein mediating their interaction. Knockdown of SPOP increases BRMS1 protein levels and represses expression of BRMS1 target genes OPN and uPA.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, Western blot of target genes\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus ubiquitination assay plus functional target gene readout, single lab\",\n      \"pmids\": [\"22085717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The crystal structure of BRMS1 residues 51–98 reveals an antiparallel coiled-coil motif that homo-oligomerizes as a hexamer (trimer of coiled-coil dimers) in solution, as confirmed by hydrodynamic experiments. This N-terminal coiled-coil region mediates molecular recognition relevant to partner binding and cellular localization.\",\n      \"method\": \"X-ray crystallography, hydrodynamic/biophysical experiments (sedimentation, size-exclusion chromatography)\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with corroborating biophysical validation; single lab but rigorous structural determination\",\n      \"pmids\": [\"21777593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BRMS1 has an E3 ubiquitin ligase function: it induces polyubiquitination of the histone acetyltransferase p300, leading to proteasome-mediated degradation of p300. The evolutionarily conserved CXD motif in BRMS1 is responsible for this E3 ligase activity; mutation of this motif abolishes p300 ubiquitination/degradation and dramatically reduces BRMS1 metastasis suppressor function in vitro and in vivo.\",\n      \"method\": \"Ubiquitination assay, CXD motif mutagenesis, proteasome inhibitor experiments, in vitro and in vivo metastasis models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — novel enzymatic activity demonstrated with mutagenesis of catalytic motif plus functional metastasis readout; confirmed by independent study (PMID 25675294)\",\n      \"pmids\": [\"23269275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NLS2 (C-terminal putative NLS, amino acids 238–244) of BRMS1 is not required for nuclear localization per se but is critical for metastasis suppression. BRMS1 and BRMS1(NLS2,2) (where NLS2 is functional) co-immunoprecipitate with SIN3A in both nucleus and cytoplasm and down-regulate miR-10b, whereas NLS1-containing variants that are nuclear-only do not suppress metastasis or down-regulate miR-10b.\",\n      \"method\": \"NLS substitution mutagenesis, xenograft metastasis model, co-immunoprecipitation, miR-10b quantification\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean mutagenesis with in vivo functional readout and mechanistic co-IP, single lab\",\n      \"pmids\": [\"23390556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BRMS1 expression reduces activation of β1 integrin and focal adhesion kinase (FAK) and decreases their localization to focal adhesion sites, without altering integrin monomer expression levels; BRMS1-expressing cells fail to reorganize their cytoskeleton and form invasive colonies under 3D culture conditions.\",\n      \"method\": \"Time-lapse and confocal microscopy, 3D culture, immunofluorescence for β1 integrin/FAK activation\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct imaging-based localization tied to functional consequence; single lab\",\n      \"pmids\": [\"24000122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Loss of BRMS1 promotes EMT in NSCLC cells in a manner dependent on RelA/p65 (NF-κB); ChIP analysis shows that loss of BRMS1 increases RelA/p65 K310 occupancy at the Twist1 promoter, activating Twist1 transcription. Knockdown of Twist1 reverses BRMS1-loss-mediated EMT phenotypes; double BRMS1(KD)/Twist1(KD) cells are less efficient in establishing lung tumors in vivo.\",\n      \"method\": \"shRNA knockdown, ChIP, EMT marker immunoblotting, migration assay, in vivo lung tumor model\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (double KD) with ChIP mechanistic validation and in vivo phenotype; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"25368381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"iASPP stabilizes p300 and CBP by interfering with BRMS1-mediated ubiquitination of these acetyltransferases; BRMS1 can rescue degradation of p300 and CBP in iASPP-depleted cells, and iASPP overexpression partially abolishes the BRMS1–CBP interaction upon DNA damage, thereby contributing to apoptotic susceptibility.\",\n      \"method\": \"shRNA depletion, co-immunoprecipitation, Western blot of p300/CBP levels, rescue assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and rescue experiments confirming BRMS1 E3 ligase activity on CBP as well as p300; single lab\",\n      \"pmids\": [\"25675294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TNF-induced CK2α' phosphorylates nuclear BRMS1 on serine 30 (S30), triggering 14-3-3ε-mediated nuclear export, increased cytosolic BRMS1 accumulation, and subsequent ubiquitin-proteasome degradation; S30 mutation or CK2 inhibition (CX4945) abrogates this process and reduces NSCLC metastasis ~60-fold in an orthotopic mouse model.\",\n      \"method\": \"Site-directed mutagenesis (S30), co-immunoprecipitation with 14-3-3ε, CK2-specific inhibitor, subcellular fractionation, orthotopic xenograft\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — phosphorylation site mutagenesis, defined kinase, pharmacological rescue, and in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"26980766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRMS1 is phosphorylated on serine 237 by CDK2; this phosphorylation does not affect cell cycle progression, nuclear localization, or mSin3/HDAC complex association or transcriptional repressor activity, but does affect cancer cell migration.\",\n      \"method\": \"In vitro kinase assay, phospho-site mutagenesis (S237), co-immunoprecipitation with mSin3, migration assay, cell cycle analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — kinase assay with mutagenesis and functional migration readout; single lab\",\n      \"pmids\": [\"26771717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BRMS1 is an integral component of the LSD1/CoREST corepressor complex; affinity purification and mass spectrometry identified this interaction, and BRMS1 together with LSD1 are required for inhibition of breast cancer cell migration and invasion. RNA-seq identified target genes regulated by the BRMS1/LSD1 complex including VIM, INSIG2, KLK11, and others.\",\n      \"method\": \"Affinity purification, mass spectrometry, RNA-seq, migration/invasion assays with LSD1 knockdown\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass spectrometry-confirmed complex with functional epistasis; single lab\",\n      \"pmids\": [\"30416854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FANCI is a novel interacting protein of BRMS1; the linker region between the two coiled-coil motifs of BRMS1 mediates the BRMS1–FANCI interaction. Knockdown or knockout of BRMS1 diminishes monoubiquitination of FANCI and FANCD2 in response to DNA interstrand crosslink (ICL) damage, suppresses FANCD2 foci formation, and causes hypersensitivity to ICL agents; rescue with BRMS1 constructs unable to bind FANCI fails to restore ICL resistance.\",\n      \"method\": \"Co-immunoprecipitation, BRMS1 deletion constructs, ubiquitination assay, FANCD2 foci immunofluorescence, ICL sensitivity assay, BRMS1 knockout\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, functional epistasis via rescue constructs, and multiple DNA damage assays; single lab\",\n      \"pmids\": [\"30365131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRIM7 ubiquitinates BRMS1, promoting its degradation; this is the mechanism through which TRIM7 regulates osteosarcoma cell migration and invasion. Loss of TRIM7 m6A modification (mediated by METTL3/YTHDF2) accounts for aberrant TRIM7 levels.\",\n      \"method\": \"Immunoprecipitation, mass spectrometry, ubiquitination assay, pulldown, immunofluorescence, RNA immunoprecipitation for m6A\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay with co-IP and functional migration/invasion readout; single lab\",\n      \"pmids\": [\"32853985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"JARID1C (a histone demethylase) represses BRMS1 transcription by modulating H3K4me3 levels at the BRMS1 gene promoter; JARID1C silencing dramatically increases BRMS1 expression, and BRMS1 knockdown reverses shJARID1C-induced migration inhibition.\",\n      \"method\": \"siRNA knockdown, ChIP for H3K4me3, qRT-PCR/Western blot, migration/invasion assays, rescue experiment\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for specific histone mark at BRMS1 promoter with epistasis rescue; single lab\",\n      \"pmids\": [\"26182878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ING4 is induced by BRMS1 and functions downstream of BRMS1 to inhibit melanoma angiogenesis; ING4 suppresses NF-κB activity and IL-6 expression. Knockdown of ING4 abrogates BRMS1's suppressive effect on HUVEC growth, and ING4 overexpression blocks BRMS1 knockdown-induced angiogenesis—establishing ING4 as a downstream effector of BRMS1.\",\n      \"method\": \"siRNA/overexpression epistasis, HUVEC growth/tube formation assays, NF-κB reporter, IL-6 ELISA, in vivo matrigel plug assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with double knockdown/overexpression rescue; single lab\",\n      \"pmids\": [\"21056991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DAPK1 is a direct transcriptional target activated by BRMS1; BRMS1 binds to NF-κB binding sites in the DAPK1 promoter (−200 to −80 bp region) as shown by ChIP, and site-directed mutation of these NF-κB sites abolishes the BRMS1-dependent transcriptional activation of DAPK1.\",\n      \"method\": \"Microarray, qRT-PCR, Western blot, luciferase promoter deletion assays, ChIP, site-directed mutagenesis of NF-κB sites\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and mutagenesis confirm direct promoter binding and functional activation; single lab\",\n      \"pmids\": [\"28339067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BRMS1 directly binds to the SCIN (scinderin) promoter and represses its transcription; knockdown of SCIN sensitizes HCC cells to chemotherapeutic drugs and suppresses tumor growth, while SCIN overexpression protects against apoptosis.\",\n      \"method\": \"ChIP (BRMS1 at SCIN promoter), FACS apoptosis analysis, caspase-9 immunoblot, in vivo xenograft\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP evidence of promoter binding with functional apoptosis readout; single lab\",\n      \"pmids\": [\"30034938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The BRMS1v2 A273V SNP (rs1052566) abolishes the metastasis suppressor function of BRMS1v2; mechanistically, BRMS1v2 A273V fails to interact with nuclear Src, thereby activating intratumoral c-fos, which upregulates CEACAM6 to drive metastases. Wild-type BRMS1v2 interaction with nuclear Src suppresses c-fos-mediated transcriptional regulation.\",\n      \"method\": \"Next-generation sequencing, co-immunoprecipitation (Src interaction), in vitro invasion assays, tail-vein and intracardiac PDO xenograft models, pharmacological c-fos inhibition (T5224)\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — SNP mutagenesis combined with co-IP mechanism, multiple in vivo models, and pharmacological rescue; single lab with rigorous multi-model validation\",\n      \"pmids\": [\"36197962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRMS1 expression restores P2Y2 purinergic receptor levels and ATP-induced cytosolic calcium mobilization in MDA-MB-435 breast cancer cells to levels comparable to non-metastatic epithelial cells, sensitizing cells to ATP-induced growth suppression.\",\n      \"method\": \"P2Y2 expression analysis, calcium mobilization assay, proliferation assay with ATP treatment\",\n      \"journal\": \"BioResearch open access\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single assay set showing receptor level restoration and calcium signaling; single lab, no mechanistic dissection of how BRMS1 regulates P2Y2\",\n      \"pmids\": [\"23593560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BRMS1 interacts with Hsp27 in complex in MCF7 breast cancer cells, as identified by immunoprecipitation of endogenous BRMS1 complexes followed by mass spectrometry.\",\n      \"method\": \"Immunoprecipitation of endogenous BRMS1 from MCF7 cells, mass spectrometry identification\",\n      \"journal\": \"Protein expression and purification\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single immunoprecipitation/MS identification; no functional follow-up on the interaction\",\n      \"pmids\": [\"19401233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BRMS1 attenuates TGF-β1-induced breast cancer EMT and invasion by downregulating HIF-1α transcript through inactivation of NF-κB; HIF-1α is required for TGF-β1-induced Snail and TWIST1 expression, and BRMS1 reduces both via the NF-κB/HIF-1α axis.\",\n      \"method\": \"ChIP, luciferase reporter assay, qRT-PCR, immunoblotting, Matrigel invasion assay\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assays validate NF-κB/HIF-1α/Snail-TWIST1 cascade; single lab\",\n      \"pmids\": [\"26520789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Phosphorylation status at BRMS1 S237 regulates its protein interaction network: S237 presence is associated with interactions related to cell cycle (CDKN2A), DNA repair (BRCA1), and metastasis (TCF2, POLE2), and directly decreases MDA-MB-231 migration in vitro and metastases in vivo; the C-terminus of BRMS1 is critical for metastasis suppression.\",\n      \"method\": \"Affinity purification-mass spectrometry (AP-MS) of BRMS1 interactome with S237 mutants, in vitro migration assay, in vivo metastasis model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative interactome with phospho-mutants plus in vivo validation; single lab\",\n      \"pmids\": [\"34788285\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRMS1 is a predominantly nuclear metastasis suppressor that functions as a component of mSin3/HDAC and LSD1/CoREST chromatin remodeling complexes to repress transcription of pro-metastatic genes (e.g., OPN, uPA, SCIN) and activate pro-apoptotic targets (DAPK1); it also possesses an intrinsic CXD-motif-dependent E3 ubiquitin ligase activity that degrades the histone acetyltransferase p300/CBP; its stability and localization are post-translationally regulated by Hsp90 chaperone stabilization, Cul3-SPOP- and TRIM7-mediated ubiquitination/degradation, and CK2α'-dependent phosphorylation at S30 that triggers 14-3-3ε-mediated nuclear export and proteasomal degradation, while CDK2-mediated phosphorylation at S237 regulates its interaction network and cell migration without affecting its chromatin complex association or nuclear localization; nuclear BRMS1 interacts with Src to suppress c-fos-dependent transcriptional programs driving metastasis, and BRMS1 also restores gap junctional intercellular communication, suppresses NF-κB activity, and participates in DNA interstrand crosslink repair by supporting FANCI/FANCD2 monoubiquitination.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BRMS1 is a nuclear metastasis suppressor that blocks multiple steps of the metastatic cascade — transit survival, anoikis resistance, and colonization at secondary sites — without affecting primary tumorigenicity in breast carcinoma and melanoma models [#0, #3, #7]. Mechanistically it operates as a chromatin-associated transcriptional regulator: it is a stable component of the mSin3A/HDAC corepressor complex, interacting with RBP1/RBBP1 and multiple HDAC subunits to repress transcription when tethered to a promoter [#2, #4], and it is also an integral subunit of the LSD1/CoREST corepressor complex required for suppression of migration and invasion [#19]. Through these activities, and by abrogating NF-\\u03baB activity, BRMS1 represses pro-metastatic genes including osteopontin and uPA [#6, #10] and the apoptosis-protective gene SCIN [#25], while activating the pro-apoptotic target DAPK1 via NF-\\u03baB sites in its promoter [#24]; loss of BRMS1 conversely de-represses RelA/p65-driven Twist1 transcription to promote EMT [#15]. Independent of its corepressor role, BRMS1 possesses an intrinsic, CXD-motif-dependent E3 ubiquitin ligase activity that polyubiquitinates and degrades the acetyltransferases p300 and CBP, an activity essential for its metastasis-suppressor function [#12, #16]. BRMS1 abundance and localization are tightly controlled post-translationally: it is stabilized by Hsp90 [#5], targeted for degradation by the Cul3-SPOP and TRIM7 ubiquitin ligases [#10, #21], and exported from the nucleus and degraded following CK2\\u03b1'-mediated S30 phosphorylation and 14-3-3\\u03b5 binding in response to TNF [#17]. Its transcription is silenced epigenetically through NF-\\u03baB/DNMT-1-mediated promoter methylation and JARID1C-mediated H3K4me3 modulation [#9, #22]. Beyond gene regulation, BRMS1 supports DNA interstrand crosslink repair by promoting FANCI/FANCD2 monoubiquitination through a direct FANCI interaction [#20], and a metastasis-suppressing splice variant interacts with nuclear Src to restrain c-fos-driven transcriptional programs [#26].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established BRMS1 as a bona fide metastasis suppressor by showing it blocks dissemination without blocking primary tumor growth, defining the central question of how a single gene selectively controls metastasis.\",\n      \"evidence\": \"Differential display and stable BRMS1 transfection into MDA-MB-435/231 breast carcinoma cells in orthotopic xenografts; GJIC and motility assays\",\n      \"pmids\": [\"10850410\", \"11827072\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular effectors of suppression not identified\", \"Mechanism of gap junction restoration unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Generalized BRMS1 suppressor activity beyond breast cancer, showing the same metastasis-selective phenotype and GJIC restoration in melanoma.\",\n      \"evidence\": \"Stable transfection and orthotopic xenograft in MelJuSo and C8161.9 melanoma lines, collagen sandwich invasion assays\",\n      \"pmids\": [\"11822878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No molecular mechanism dissected\", \"Single lab\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the molecular basis of BRMS1 transcriptional repression by placing it within the mSin3A/HDAC corepressor complex, explaining how it silences target genes.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, biochemical purification, HDAC enzymatic assays, and Gal4 reporter repression\",\n      \"pmids\": [\"14581478\", \"15451426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes not yet identified\", \"Whether repression alone explains metastasis suppression unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected BRMS1's corepressor activity to a specific pro-metastatic gene, showing it suppresses osteopontin by abrogating NF-\\u03baB at the promoter.\",\n      \"evidence\": \"Luciferase OPN promoter deletions, EMSA, and ChIP with HDAC3\",\n      \"pmids\": [\"17227585\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect NF-\\u03baB inhibition not fully resolved\", \"Single target gene\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved which steps of the metastatic cascade BRMS1 blocks, showing it reduces transit survival and colonization and increases anoikis susceptibility.\",\n      \"evidence\": \"Cardiac injection xenografts with quantitative imaging and poly-HEMA anoikis assays\",\n      \"pmids\": [\"18276787\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between transcriptional role and anoikis sensitivity not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the nucleocytoplasmic trafficking of BRMS1, identifying an importin-\\u03b16-dependent NLS and a CRM1-independent NES, establishing it as a shuttling protein.\",\n      \"evidence\": \"Import/export reporter assays, directed Y2H, leptomycin-B, heterokaryon assays\",\n      \"pmids\": [\"19649328\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of shuttling not yet linked to suppression\", \"Export receptor identity unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established post-translational control of BRMS1 abundance via Cul3-SPOP ubiquitination and transcriptional silencing via NF-\\u03baB/DNMT-1 promoter methylation, plus a structural basis for oligomerization.\",\n      \"evidence\": \"Co-IP/ubiquitination assays with SPOP knockdown; ChIP and methylation-specific PCR with RelA S276 mutagenesis; X-ray crystallography of residues 51-98\",\n      \"pmids\": [\"22085717\", \"21765477\", \"21777593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between degradation and methylation pathways not integrated\", \"Functional role of hexameric coiled-coil oligomerization in vivo untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed an unexpected enzymatic function — intrinsic CXD-motif E3 ligase activity degrading p300 — required for metastasis suppression, distinguishing it from passive corepression.\",\n      \"evidence\": \"Ubiquitination assays, CXD motif mutagenesis, proteasome inhibition, and in vivo metastasis models\",\n      \"pmids\": [\"23269275\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ligase activity unresolved\", \"Full substrate repertoire beyond p300/CBP unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Dissociated nuclear localization from function, showing the C-terminal NLS2 region and SIN3A co-localization (not mere nuclear residence) and miR-10b downregulation are required for suppression.\",\n      \"evidence\": \"NLS substitution mutagenesis, xenograft metastasis, co-IP with SIN3A, miR-10b quantification; integrin/FAK imaging in 3D culture\",\n      \"pmids\": [\"23390556\", \"24000122\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking BRMS1 to miR-10b not defined\", \"How BRMS1 reduces integrin/FAK activation unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established the EMT axis of BRMS1 loss, showing it restrains RelA/p65-driven Twist1 transcription via promoter occupancy.\",\n      \"evidence\": \"shRNA knockdown, ChIP at Twist1 promoter, double BRMS1/Twist1 knockdown epistasis, in vivo lung tumor model\",\n      \"pmids\": [\"25368381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BRMS1 acts directly at Twist1 or via global NF-\\u03baB suppression unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended the E3 ligase activity to CBP and identified iASPP as an antagonist, and mapped additional NF-\\u03baB-dependent suppression of HIF-1\\u03b1/EMT and JARID1C-mediated epigenetic silencing of BRMS1.\",\n      \"evidence\": \"shRNA depletion and rescue co-IP for iASPP/CBP; ChIP/reporter for NF-\\u03baB/HIF-1\\u03b1/Snail-TWIST1; ChIP for H3K4me3 at BRMS1 promoter\",\n      \"pmids\": [\"25675294\", \"26520789\", \"26182878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative balance of competing ligase/antagonist interactions unclear\", \"Multiple converging pathways not integrated mechanistically\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined kinase-driven regulation: TNF/CK2\\u03b1' phosphorylation at S30 drives 14-3-3\\u03b5-mediated export and degradation, while CDK2 phosphorylation at S237 selectively tunes migration without altering corepressor activity.\",\n      \"evidence\": \"Phospho-site mutagenesis (S30, S237), kinase assays, CK2 inhibitor CX4945, 14-3-3\\u03b5 co-IP, fractionation, migration and orthotopic models\",\n      \"pmids\": [\"26980766\", \"26771717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How S237 phosphorylation alters the interaction network mechanistically incomplete at this stage\", \"Crosstalk between phosphorylation and ubiquitination pathways unmapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified DAPK1 as a directly BRMS1-activated pro-apoptotic target, showing BRMS1 can also positively regulate transcription via NF-\\u03baB sites.\",\n      \"evidence\": \"Microarray, luciferase promoter deletions, ChIP, and NF-\\u03baB site mutagenesis in the DAPK1 promoter\",\n      \"pmids\": [\"28339067\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How BRMS1 switches from repressor to activator at NF-\\u03baB sites unexplained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Broadened BRMS1's chromatin partnerships to the LSD1/CoREST complex, identified the SCIN promoter as a repressed apoptosis-protective target, and revealed a non-transcriptional role in FANCI/FANCD2-dependent ICL repair.\",\n      \"evidence\": \"Affinity purification-MS and RNA-seq with LSD1 knockdown; ChIP at SCIN promoter with apoptosis assays; co-IP and FANCD2 foci/ICL sensitivity assays with BRMS1 knockout and binding-dead rescue\",\n      \"pmids\": [\"30416854\", \"30034938\", \"30365131\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relationship between mSin3 and LSD1/CoREST complex membership not resolved\", \"Mechanism by which BRMS1 supports FANCI/FANCD2 monoubiquitination unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Added a second degradative ligase, TRIM7, and linked its m6A regulation to BRMS1 turnover in osteosarcoma, expanding the post-translational control network.\",\n      \"evidence\": \"IP-MS, ubiquitination assays, pulldown, and m6A RIP with METTL3/YTHDF2\",\n      \"pmids\": [\"32853985\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specificity of SPOP vs TRIM7 control unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected a clinically relevant SNP to a discrete mechanism: BRMS1v2 A273V loses nuclear Src binding, de-repressing c-fos and CEACAM6 to drive metastasis.\",\n      \"evidence\": \"NGS, co-IP for Src interaction, invasion assays, tail-vein/intracardiac PDO xenografts, and c-fos inhibition (T5224)\",\n      \"pmids\": [\"36197962\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How nuclear Src binding mechanistically restrains c-fos transcription not fully defined\", \"Generalizability across cancer types untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BRMS1's distinct activities — corepressor membership, intrinsic E3 ligase activity, DNA-repair support, and nuclear Src signaling — are coordinated and which dominates metastasis suppression in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating chromatin, ubiquitination, and repair roles\", \"Endogenous structural organization of BRMS1 within its complexes unknown\", \"Substrate selectivity of the BRMS1 E3 ligase undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 4, 6, 24, 25]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [12, 16]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [12, 16]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 8, 13, 17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8, 13, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 6, 15, 24, 25]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [2, 4, 19, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 3, 26]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [10, 12, 17, 21]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"complexes\": [\"mSin3A/HDAC corepressor complex\", \"LSD1/CoREST corepressor complex\"],\n    \"partners\": [\"SIN3A\", \"RBBP1\", \"HDAC1\", \"LSD1\", \"SPOP\", \"TRIM7\", \"FANCI\", \"EP300\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}